Molindone

Molindone is a combination medication used for the management of schizophrenia.

• Molindone is available under the following different brand names: Moban

Common side effects of Molindone include:

• dizziness
• drowsiness
• depression
• restlessness
• agitation
• blurred vision
• dry mouth
• breast swelling or discharge
• changes in the menstrual cycle
• nausea
• constipation
• changes in weight

Serious side effects of Molindone include:

• very stiff (rigid) muscles
• high fever
• sweating
• confusion
• fast or uneven heartbeats
• lightheadedness
• restless muscle movements in the eyes, tongue, jaw, or neck
• tremors (uncontrolled shaking)
• trouble swallowing
• seizures (convulsions)
• easy bruising or bleeding
• unusual weakness
• chills
• body aches
• flu symptoms
• severe constipation
• urinating less than usual or not at all

Rare side effects of Molindone include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, light-headedness, or passing out

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Tablet

• 5 mg
• 10 mg
• 25 mg
• 50 mg

Schizophrenia

Adult dosage

• Initial: 50-75 mg orally every day; increase to 100 mg/day in 3-4 days; may titrate up or down based on the severity of symptomatology and individual patient response

Maintenance

• Mild: 5-15 mg orally every 6-8 hours
• Moderate: 10-25 mg orally every 6-8 hours
• Severe: 225 mg/day orally may be required

Dosage Considerations – Should be Given as Follows:

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Molindone has severe interactions with no other drugs
• Molindone has serious interactions with the following drugs:
  • benzhydrocodone/acetaminophen
  • hydrocodone
  • metoclopramide intranasal
  • olopatadine intranasal
  • selinexor
  • sufentanil SL
• Molindone has moderate interactions with at least 58 other drugs
• Molindone has minor interactions with no other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• Documented hypersensitivity
• Severe central nervous system depression (eg, alcohol, barbiturates, narcotics) or comatose states

Effects of drug abuse

• None

Short-Term Effects

• See "What Are Side Effects Associated with Using Molindone?"

Long-Term Effects

• See "What Are Side Effects Associated with Using Molindone?"

Cautions

• Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs; if signs and symptoms of tardive dyskinesia appear in patients on antipsychotics, consider drug discontinuation; however, some patients may require treatment despite presence of the syndrome
• May cause drowsiness, postural hypotension, motor instability, and sensory instability, which may lead to falls and, consequently, fractures or other injuries; complete fall-risk assessments for patients with diseases, conditions, or medications that could exacerbate these effects, when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy
• Neuroleptic malignant syndrome (NMS) reported with antipsychotic drug use; immediately discontinue therapy if it occurs along with nonessential concurrent therapy and administer intensive symptomatic treatment and monitor carefully; if the patient requires antipsychotic drug treatment after recovery from NMS, it should be considered carefully, and the patient should be monitored closely because recurrences of NMS have been reported
• May cause drowsiness initially; advise the patient against activities requiring mental alertness until response to the drug has been established
• Convulsive seizures reported with the use
• The preparation contains calcium sulfate as an excipient; calcium ions may interfere with the absorption of preparations containing phenytoin sodium and tetracyclines
• Therapy may obscure signs of intestinal obstruction or brain tumor
• Antipsychotic drugs elevate prolactin levels; elevation persists during long-term administration; although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels are unknown for most patients
• Therapy has not been effective in the management of behavioral complications in patients with mental retardation
• In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported temporally related to antipsychotic agents; possible risk factors for leukopenia/neutropenia include preexisting low white blood cell (WBC) count and history of drug-induced leukopenia/neutropenia; patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur; patients with severe neutropenia (absolute neutrophil count less than 1000/mm3) should discontinue therapy and have their WBC count followed until recovery

Pregnancy and Lactation

• Studies in pregnant women have not been performed; animal reproductive studies have not demonstrated a teratogenic potential; anticipated benefits must be weighed against unknown risks to the fetus if used in pregnant women
• Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at a risk for extrapyramidal and/or withdrawal symptoms following delivery; agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorders reported in neonates; complications have varied in severity; while in some cases symptoms have been self-limited, in other cases, neonates have required intensive care unit support and prolonged hospitalization
• Lactation
  • Data are not available on the content of molindone hydrochloride in the milk of nursing mothers